Sale of Fisons' scientific instruments delayed:
This article was originally published in Clinica
Embroiled in fighting a hostile bid from Rhone-Poulenc Rorer as Clinica went to press, UK pharmaceuticals company Fisons is suffering further delays to the disposal of its scientific instruments division. After a third delay, the new completion date of the sale to US-based Thermo Instrument Systems is November 17th. Thermo says it expects further delays before receiving the US Federal Trade Commission's go-ahead. As for the bid for Fisons, RPR has increased its offer to 265 pence from 240 pence previously.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.